Quarterly ResultApr 29, 2026, 07:02 AM
TEVA to Acquire Emalex; Q1 Revenue $4.0B, EPS $0.31
AI Summary
Teva announced its Q1 2026 results, reporting revenues of $4.0 billion, a 2% increase YoY in U.S. dollars, and GAAP diluted EPS of $0.31. The company also revealed its definitive agreement to acquire Emalex Biosciences, adding an NDA-ready therapy to its neuroscience pipeline, expected to close by Q3 2026. Key innovative brands like AUSTEDO, AJOVY, and UZEDY drove significant growth, collectively increasing 41% YoY in local currency, while generics revenue decreased due to competition for lenalidomide. Teva maintained its 2026 business outlook, adjusted for the Emalex transaction, and the Board instructed management to plan for a share repurchase program.
Key Highlights
- TEVA to acquire Emalex Biosciences, adding an NDA-ready therapy to its neuroscience pipeline, expected to close by Q3 2026.
- Q1 2026 revenues of $4.0 billion, an increase of 2% YoY in U.S. dollars.
- GAAP diluted EPS of $0.31 and Non-GAAP diluted EPS of $0.53.
- AUSTEDO global revenues grew 41% YoY in local currency to $578 million.
- AJOVY global revenues increased 35% YoY in local currency to $196 million.
- UZEDY revenues increased 62% YoY in local currency to $63 million.
- Global generics revenues decreased 16% YoY in local currency, mainly due to increased lenalidomide competition.
- Board of Directors instructed management to plan for a share repurchase program.
- 2026 revenue outlook maintained at $16.4 - $16.8 billion (adjusted for Emalex transaction).